To order this 250+ page report, which features 120+ figuresand 135+ tables, please visit this link
The over USD 6.5 billion (by2030) financial opportunity within the psychedelic therapeutics market has beenanalyzed across the following segments:
§ TargetDisease Indication
- Anxiety and Depression
- Trauma
- Pain Disorder
- Sleep related Disorder
§ Origin ofPsychedelic Substance
- Natural
- Synthetic
§ Type ofPsychedelic Substance
- Gamma-hydroxybutyrate
- Ketamine
- MDMA
- Psilocybin
§ Route ofAdministration
- Oral
- Intranasal
- Sublingual
§ KeyGeographies
- North America
- Europe
- Asia-Pacific
The Global Psychedelic TherapeuticsMarket, 2020-2030 reportfeatures the following companies, which we identified to be key players in thisdomain:
§ CelonPharma
§ iXBiopharma
§ MAPSPublic Benefit
§ MindMed
§ JanssenPharmaceuticals
§ JazzPharmaceutical
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape: Psychedelic Therapeutics
5. Company Profiles
6. Clinical Trial Analysis
7. Clinical Trial Site Analysis
9. Key Opinion Leader (KOL) Analysis
8. Academic Grants Analysis
10. Partnerships and Collaborations
11. Mergers and Acquisitions
12. Market Forecast and Opportunity Analysis
13. Concluding Remarks
14. Executive Insights
15. Appendix 1: Tabulated Data
16. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
